TABLE 5.
Other parameters
| Items investigated | After 12 weeks of oxytocin | After 12 weeks of placebo | P * | ||
|---|---|---|---|---|---|
| Median | IQR | Median | IQR | ||
| ∆AG (pg/ml) a (N = 12) | ‐10.6 | (−88.1 to 34.2) | 17.4 | (−53.6 to 47.9) | 0.27 |
| ∆UAG (pg/ml) a (N = 11) | 13.0 | (−34.6 to 32.8) | 12.7 | (−123.2 to 95.3) | 0.42 |
| ∆AG/UAG ratio (pg/ml) a (N = 11) | ‐0.14 | (−0.52 to 0.26) | 0.0 | (−0.29 to 0.63) | 0.25 |
| Oxytocin in serum (pg/ml) (N = 13) | 4106 | (3065‐8027) | 4264 | (3371‐6381) | 0.31 |
| ∆ Oxytocin in serum (pg/ml) | 786 | (−168 to 2896) | 363 | (−475 to 1775) | 0.27 |
a
a positive score indicates a higher AG or UAG or AG/UAG ratio at the end of the OX/PL period.
*
P‐value between oxytocin and placebo phase.